Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond
Author:
Affiliation:
1. Division of Pulmonary Oncology, Azienda Ospedaliera Dei Colli Monaldi, Naples, Italy
2. Luigi Vanvitelli University, Caserta, Italy
3. Division of Medical Oncology, AORN Giuseppe Moscati, Avellino, Italy
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,General Medicine
Reference78 articles.
1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy.
2. Lemmon MA, and Schlessinger J. Cell signaling by receptor tyrosine kinases.
3. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities.
4. Zhang Y-L, Yuan J-Q, Wang K-F. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
5. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting;Journal of Molecular Pathology;2023-04-30
2. Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations;Journal of Cancer Research and Clinical Oncology;2022-08-26
3. Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells;Cell Death Discovery;2022-03-18
4. Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities;Tumori Journal;2022-02-04
5. Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions;Expert Review of Precision Medicine and Drug Development;2022-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3